The upside potential for OPHT just got a whole lot more interesting. awe.some*sto-cks recently alerted this company i think. google them.
I think they way i read this, going down because of Roche's failed drug that is similar to fovista which OPHT isn't testing anymore. So why would it go down?
Company already reported failure and consequently the stock went up which I didn't understand. So why now the big drop?
Company expects year end cash (2017) to be between $145m to $160m taking into account all other expenses. Market cap $90m. What do you think? How valuable is the pipeline?
Well is very bearish right now!
Man no one is hyping this stock! There has to be a few longs than just ole me!
Wow trading under cash value for so long now. How longer?
Shares of the biotech Ophthotech Corporation plummeted 10.3% to $2.78 in heavy Friday trade. Ophthotech's macular degeneration therapy pegpleranib, tested in combination with other therapies, did not show benefit compared to the other therapies alone, the company said in mid-August. The company plans to move forward "with multiple ongoing or planned clinical programs in orphan retinal diseases," it said in August. Roche shares have declined 1% over the last three months and Ophthotech shares have risen 9%, compared with a 1% rise in the S&P 500.
negative results for similar to Roche drug. Didn't think zimura was due now
Just re hashed news. picked up some share up now for a good run on zimura
$OPHT check out OTIC oversold from $20's
Last 14 minutes stock down 12% down 36 cents and still dropping No news.... negative insider info
Why is ophthotech down 11% just now
Anyone here know whatever became f this research from 2014?
CAMBRIDGE, Mass.—NOV 11, 2014— AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
QUIET WITH THE AWESOME STOCK PROMOTING!!
JIM-- YOU WANT TO EXPLAIN THIS PLEASE. WHAT'S THE BOTTOM LINE HERE?
A third phase 3 failure for Fovista provides a good claim to short the stock Other clinical trial readouts are at least one year or more away, meaning no cataly
Seeking alpha LMAO.. Novartis pulling out on partnership, gives back 50mln for one, 125 mln debt goes bye bye. Clean shell with 4.50 end of year.
"Wendy" I hope you got my message. why didn't you say so? once you told me that, all the other messages go away. miss you on the other board . hope all is well with you
SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.